T Cell Antigen Gp39 is a special type of protein, usually used to regulate the T-cell activation, which plays a significant role in the autoimmune diseases, transplantation tolerance, and cancer. It is also used in the inducing cells to become regulatory T cells or Tregs. T Cell Antigen Gp39 is generally involved in the activation & proliferation of T cells and is also essential for the development of immunity. Presence of T cell Antigen Gp39 on the surface of tumor-cells can also be used to target & kill tumor-cells. T cell antigen gp39 is also recognized as CD40 ligand or CD154, which is a member of the TNF super-family, and has been proved to be very effective in the management of graft versus host disease (GVHD) by inhibiting the immune response.
As per analysis, Global T Cell Antigen Gp39 Industry Research Report 2021 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2027. Some of the key companies operating in the global T cell antigen Gp39 market include Juno Therapeutics Inc, Biogen, Inc., eTheRNA Immunotherapies NV, XL-protein GmbH, ImmuNext, Inc., Bristol-Myers Squibb Company, Targovax AS, MedImmune, LLC and among others. To improve their market positions in the global T Cell Antigen Gp39 market, key players are now focusing on adopting different strategies for instance recent developments, joint ventures, collaborations, mergers and acquisitions, product innovations and partnerships.
Request For Sample Report-https://kenresearch.com/sample-report.php?Frmdetails=NDQ0NzAx
Based on types, T cell antigen Gp39 market can be segmented as Hepatitis B vaccine, ECI-006, ISF-35, INX-021 and others. Hepatitis B vaccine is commonly used to treat patient with chronic hepatitis B infection. The vaccine helps the body’s immune system to fight-off infection by the hepatitis-B virus. ECI-006 is a recombinant and humanized IgG antibody particular for T cell antigen gp39. It is very effective in the treatment of numerous autoimmune diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. In addition, based on application, market can be segmented as bladder cancer, graft versus host disease, breast cancer, pancreatic cancer and others. Bladder cancer helps kill cancer cells and stops them from spreading. It also stimulates the immune system to fight cancer cells. Graft versus host disease is a protein that helps to control the activation & survival of T cells that play a key role in causing graft versus host disease. Additionally, breast cancer helps body’s immune system to recognize and attack the tumor cells. The protein helps to identify the tumors and also helps in the improvement of immunotherapy treatments for the disease.
Based on regional analysis, the North-America is a leading region in global T cell antigen Gp39 market owing to rise in demand for adoptive cell therapy across the region. The Asia-Pacific and Europe regions are anticipated to exhibit substantial growth rate due to growth in patient population and rise in investment in research & development (R&D) over the forecast period. It is projected that future of the global T cell antigen Gp39 market will be bright on account of increase in prevalence of cancer & autoimmune diseases during the forecast period.
For More Information, refer to below link:-
Global T Cell Antigen Gp39 Market Research Report
Related Reports
Follow Us
LinkedIn | Instagram | Facebook | Twitter | YouTube
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249